Hormone Receptor Positive HER2 Negative Breast Cancer
specificThe reemergence of hormone receptor-negative breast adenocarcinoma after a period of remission.
11
Centers
9
Active Trials
—
Cancer Funding
Top Centers for Hormone Receptor Positive HER2 Negative Breast Cancer(11)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 58.6 |
| 2 | NCI Comprehensive Active Research Program | 58.6 |
| 3 | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive Active Research Program | 58.6 |
| 4 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive Active Research Program | 58.6 |
| 5 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive Active Research Program | 58.6 |
| 6 | The University of Kansas Cancer CenterKansas City, KS NCI Comprehensive Active Research Program | 58.6 |
| 7 | Boston University Cancer CenterBoston, MA Active Research Program | 58.6 |
| 8 | Karmanos Cancer InstituteDetroit, MI NCI Comprehensive Active Research Program | 58.6 |
| 9 | Georgia Cancer Center, Augusta UniversityAugusta, GA Active Research Program | 58.6 |
| 10 | Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive | 36.1 |
| 11 | Fox Chase Cancer CenterPhiladelphia, PA NCI Comprehensive | 36.1 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →